HALO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HALO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
Halozyme Therapeutics's adjusted revenue per share for the three months ended in Sep. 2024 was $2.229. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $3.17 for the trailing ten years ended in Sep. 2024.
During the past 12 months, Halozyme Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 29.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 31.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 26.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 27.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.
During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Halozyme Therapeutics was 39.10% per year. The lowest was 17.30% per year. And the median was 26.55% per year.
As of today (2024-11-10), Halozyme Therapeutics's current stock price is $61.01. Halozyme Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was $3.17. Halozyme Therapeutics's Cyclically Adjusted PS Ratio of today is 19.25.
During the past 13 years, the highest Cyclically Adjusted PS Ratio of Halozyme Therapeutics was 79.55. The lowest was 13.00. And the median was 24.88.
The historical data trend for Halozyme Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Cyclically Adjusted Revenue per Share | Get a 7-Day Free Trial | 2.44 | 2.59 | 2.78 | 2.96 | 3.17 |
For the Biotechnology subindustry, Halozyme Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Cyclically Adjusted PS Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?
Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.
We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Halozyme Therapeutics's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Sep. 2024 (Change) | * | Current CPI (Sep. 2024) |
= | 2.229 | / | 133.0289 | * | 133.0289 | |
= | 2.229 |
Current CPI (Sep. 2024) = 133.0289.
Halozyme Therapeutics Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201412 | 0.244 | 99.070 | 0.328 |
201503 | 0.149 | 99.621 | 0.199 |
201506 | 0.323 | 100.684 | 0.427 |
201509 | 0.164 | 100.392 | 0.217 |
201512 | 0.407 | 99.792 | 0.543 |
201603 | 0.333 | 100.470 | 0.441 |
201606 | 0.261 | 101.688 | 0.341 |
201609 | 0.249 | 101.861 | 0.325 |
201612 | 0.304 | 101.863 | 0.397 |
201703 | 0.230 | 102.862 | 0.297 |
201706 | 0.252 | 103.349 | 0.324 |
201709 | 0.445 | 104.136 | 0.568 |
201712 | 1.244 | 104.011 | 1.591 |
201803 | 0.216 | 105.290 | 0.273 |
201806 | 0.245 | 106.317 | 0.307 |
201809 | 0.178 | 106.507 | 0.222 |
201812 | 0.418 | 105.998 | 0.525 |
201903 | 0.386 | 107.251 | 0.479 |
201906 | 0.269 | 108.070 | 0.331 |
201909 | 0.316 | 108.329 | 0.388 |
201912 | 0.381 | 108.420 | 0.467 |
202003 | 0.185 | 108.902 | 0.226 |
202006 | 0.400 | 108.767 | 0.489 |
202009 | 0.460 | 109.815 | 0.557 |
202012 | 0.834 | 109.897 | 1.010 |
202103 | 0.599 | 111.754 | 0.713 |
202106 | 0.924 | 114.631 | 1.072 |
202109 | 0.790 | 115.734 | 0.908 |
202112 | 0.707 | 117.630 | 0.800 |
202203 | 0.830 | 121.301 | 0.910 |
202206 | 1.071 | 125.017 | 1.140 |
202209 | 1.499 | 125.227 | 1.592 |
202212 | 1.302 | 125.222 | 1.383 |
202303 | 1.176 | 127.348 | 1.228 |
202306 | 1.655 | 128.729 | 1.710 |
202309 | 1.611 | 129.860 | 1.650 |
202312 | 1.755 | 129.419 | 1.804 |
202403 | 1.520 | 131.776 | 1.534 |
202406 | 1.790 | 132.554 | 1.796 |
202409 | 2.229 | 133.029 | 2.229 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.
For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Halozyme Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 61.01 | / | 3.17 | |
= | 19.25 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
During the past 13 years, the highest Cyclically Adjusted PS Ratio of Halozyme Therapeutics was 79.55. The lowest was 13.00. And the median was 24.88.
Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.
Thank you for viewing the detailed overview of Halozyme Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael J. Labarre | officer: SVP, Chief Technical Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Helen Torley | director, officer: President and CEO | C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Matthew L. Posard | director | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Nicole Labrosse | officer: SVP, Chief Financial Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
James M Daly | director | INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880 |
Jeffrey William Henderson | director | 7000 CARDINAL PLACE, DUBLIN OH 43017 |
Barbara Gayle Duncan | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013 |
Akiko Moni Miyashita | director | 20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501 |
Mark Howard Snyder | officer: SVP, General Counsel | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Matsui Connie | director | 3030 CALLAN RD, SAN DIEGO CA 92121 |
Jean-pierre Bizzari | director | 235 LAUREL LN, HAVERFOLD PA 19041 |
Kenneth J Kelley | director | 1331 HILLVIEW DRIVE, MENLO PARK CA 94025 |
Elaine D Sun | officer: SVP, Chief Financial Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Masaru Matsuda | officer: SVP, General Counsel | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Benjamin Hickey | officer: SVP, Chief Commerical Officer | C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121 |
From GuruFocus
By GuruFocus Research • 02-20-2024
By PRNewswire • 05-21-2024
By GuruFocus Research • 02-28-2024
By PRNewswire • 06-21-2024
By PRNewswire • 06-06-2024
By GuruFocus Research • 05-08-2024
By GuruFocus Research • 08-07-2024
By PRNewswire • 09-13-2024
By GuruFocus Research • 08-14-2024
By PRNewswire • 07-23-2024